Selank Peptide Shows Anxiolytic Effects Comparable to Benzodiazepines in New Study
Russian researchers publish comparative study showing synthetic peptide selank demonstrates anxiety-reducing effects similar to benzodiazepines without sedation or dependence risk.
A newly published study from researchers at the Institute of Molecular Genetics has reignited interest in selank, a synthetic peptide developed in Russia that demonstrates anxiolytic properties comparable to traditional benzodiazepine medications. The findings suggest selank may offer anxiety relief without the sedative effects, cognitive impairment, or dependence potential associated with conventional anti-anxiety drugs.
What We Know
The study compared selank’s effects against diazepam (Valium) and phenazepam in both animal models and a small human cohort with generalized anxiety disorder. Researchers measured anxiety-related behaviors, cognitive performance, and physiological stress markers over a 14-day treatment period [selank-comparative-2025].
Results showed selank produced anxiolytic effects of similar magnitude to the benzodiazepine comparators on standardized anxiety assessment scales. However, critical differences emerged in secondary outcomes. Participants receiving selank showed no decline in cognitive test performance, maintained normal sleep architecture, and demonstrated no signs of tolerance development over the study period.
Selank is a heptapeptide (seven amino acids) derived from the endogenous immunomodulatory peptide tuftsin, with an additional Pro-Gly-Pro sequence that enhances stability and central nervous system penetration. It has been approved for clinical use in Russia and several former Soviet states since 2009, though it remains unapproved in Western countries [institute-molecular-genetics].
Mechanism of Action
The peptide appears to work through multiple pathways rather than direct GABA receptor binding like benzodiazepines. Research indicates selank influences the expression of brain-derived neurotrophic factor (BDNF), modulates enkephalin degradation, and affects serotonin metabolism. This multi-target approach may explain both its efficacy and its favorable side effect profile [anxiety-mechanisms].
Notably, selank showed immunomodulatory effects that benzodiazepines lack. Participants demonstrated improved markers of immune function, which may be relevant given the well-established bidirectional relationship between anxiety disorders and immune dysregulation.
What It Means
These findings contribute to growing evidence that peptide-based therapies may offer alternatives to traditional small-molecule drugs for neuropsychiatric conditions. The absence of dependence potential is particularly significant given the current crisis of benzodiazepine overprescription and the documented risks of long-term use.
However, several caveats apply. The study was conducted in Russia with a relatively small sample size, and the research group has historical ties to selank’s original development. Independent replication by Western research institutions would strengthen confidence in these findings.
The regulatory pathway for selank in the United States and European Union remains unclear. Without pharmaceutical company sponsorship for the expensive clinical trials required for approval, selank may remain in a regulatory gray area in Western countries despite decades of use elsewhere.
What’s Next
International interest in peptide anxiolytics appears to be growing. Several academic institutions in Europe have initiated pilot studies examining selank and related peptides, though these remain in early stages.
The broader question of whether peptide-based neurotherapeutics can achieve mainstream acceptance in Western medicine depends partly on addressing delivery challenges. Selank is typically administered intranasally, which presents bioavailability and dosing consistency issues that would need resolution for regulatory approval.
For individuals currently managing anxiety, approved medications and evidence-based psychotherapies remain the standard of care. Selank’s regulatory status means quality control for products sold online cannot be verified, presenting safety concerns that outweigh potential benefits outside controlled research settings.
This information is provided for educational purposes only and does not constitute medical advice.
Sources & Citations
- 1journalComparative Analysis of Selank and Benzodiazepine Anxiolytic Effects
selank-comparative-2025
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.